Organ Transplant Immunosuppressive Markets : Kalorama Information

Organ Transplant Immunosuppressive Markets

Jan 1, 2008
160 Pages - Pub ID: KLI1399527

Ask a question about this report >

Email a colleague >

Printer format >

Order by fax >

Abstract

Table of Contents

Search Inside Report

Related Reports

Improved surgical techniques and organ preservation, understanding of immunologic barriers, and the development of newer and more potent immunosuppressives have combined to improve survival of transplant patients and grafts. Rejection remains the major barrier to long-term graft survival in patients, organ transplantation therapy is highly dependent on the success of immunosuppressants to suppress the recipient’s immune responses to the foreign organ.

Most transplant patients require lifelong immunosuppressive therapy to prevent rejection, except when human leukocyte antigen (HLA)-identical transplants are used. The number of organ transplants performed worldwide is approximately 70,000 annually. As medical science extends the life expectancy of patients with transplanted organs, demand continues to increase for safe, effective immunosuppressants to control transplant rejection.

Kalorama Information's Organ Transplant Immunosuppressive Markets is focused on immunosuppressants utilized in solid organ transplantation. It provides an in depth look into the trends that have shaped today’s use of transplant immunosuppression regimens, and details the current and future global market. Included in this report:

Detailed statistics on Transplant Need, Organ Transplant Procedures, Costs, Patient Waiting Lists, and Patient Survival Rates
Immunosupressive Current Market and Forecasts
Breakouts of Immunosuppressive Drugs by Drug Type and by Organ Transplanted
Regional Breakout of Immunosuppressive Sales (US, Europe, Asia/Pacific, Rest of World)
Market Share of Immunosuppressive Market
Review of Current Products and New Products in Development
Profiles of Immunosuppressive Market Competitors

As part of Kalorama Information's information-gathering process, this report consists of primary research. An exhaustive search of medical and corporate literature was conducted. But interviews with executives in the market were used to build models and test assumptions in this report.

Pharmaceutical marketing directors, executives in the organ transplant market, as well as investors looking at this market are among those who will find this report a useful resource.

Related Reports: